Terms: = Ovarian cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Clinical Outcome
10 results:
1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced ovarian cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract] [Full Text] [Related]
2. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
3. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous ovarian cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract] [Full Text] [Related]
4. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
[TBL] [Abstract] [Full Text] [Related]
5. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous ovarian cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract] [Full Text] [Related]
6. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Santegoets SJ; Dijkgraaf EM; Battaglia A; Beckhove P; Britten CM; Gallimore A; Godkin A; Gouttefangeas C; de Gruijl TD; Koenen HJ; Scheffold A; Shevach EM; Staats J; Taskén K; Whiteside TL; Kroep JR; Welters MJ; van der Burg SH
Cancer Immunol Immunother; 2015 Oct; 64(10):1271-86. PubMed ID: 26122357
[TBL] [Abstract] [Full Text] [Related]
7. The ratios of CD8+ T cells to CD4+CD25+ foxp3+ and foxp3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract] [Full Text] [Related]
8. CD4 (+)CD25 (+)foxp3 (+) regulatory T cells and hematologic malignancies.
Kelley TW; Parker CJ
Front Biosci (Schol Ed); 2010 Jun; 2(3):980-92. PubMed ID: 20515837
[TBL] [Abstract] [Full Text] [Related]
9. foxp3(+) cell infiltration and granzyme B(+)/foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract] [Full Text] [Related]
10. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.
Zeimet AG; Reimer D; Wolf D; Fiegl H; Concin N; Wiedemair A; Wolf AM; Rumpold H; Müller-Holzner E; Marth C
Int J Cancer; 2009 May; 124(10):2353-60. PubMed ID: 19170204
[TBL] [Abstract] [Full Text] [Related]
